Johnson and Johnson announced that the European Commission had approved an Advance Purchase Agreement, according to which the European Commission will be supplied with 200 million doses of COVID 19 vaccine for the EU member states. Through this agreement, the member states can further secure 200 million doses of vaccine.
The agreement comes as a conclusion to the discussions between Johnson & Johnson and the European Commission.
Johnson and Johnson announced that it would supply another 500 million doses of COVID19 vaccine to the lower-income countries after the regulatory authorities' approval.
Also read: J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine
Johnson and Johnson is currently testing the COVID-19 vaccine candidate in a multi-country Phase 3 trial (ENSEMBLE). The company is also planning to start a trial testing two-dose regimen later this year.
The COVID-19 vaccine is developed using Janssen's AdVac technology, which is used to develop the Ebola vaccine, HIV vaccine, RSV, and Zika vaccine.
To strengthen the oncology portfolio, Merck collaborated with Seattle Genetics, and Gilead acquired
For pipeline, market overview, and market access reports (syndicate and custo
mized) please write to firstname.lastname@example.org
For all syndicate reports: Click here